HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans

HIF2α is a key driver of kidney cancer. Using a belzutifan analogue (PT2399), we previously showed in tumorgrafts (TG) that ∼50% of clear cell renal cell carcinomas (ccRCC) are HIF2α dependent. However, prolonged treatment induced resistance mutations, which we also identified in humans. Here, we ev...

Full description

Bibliographic Details

Published in:	Clinical cancer research Vol. 28; no. 24; p. 5405
Main Authors:	Ma, Yuanqing, Joyce, Allison, Brandenburg, Olivia, Saatchi, Faeze, Stevens, Christina, Toffessi Tcheuyap, Vanina, Christie, Alana, Do, Quyen N, Fatunde, Oluwatomilade, Macchiaroli, Alyssa, Wong, So C, Woolford, Layton, Yousuf, Qurratulain, Miyata, Jeffrey, Carrillo, Deyssy, Onabolu, Oreoluwa, McKenzie, Tiffani, Mishra, Akhilesh, Hardy, Tanner, He, Wei, Li, Daniel, Ivanishev, Alexander, Zhang, Qing, Pedrosa, Ivan, Kapur, Payal, Schluep, Thomas, Kanner, Steven B, Hamilton, James, Brugarolas, James
Format:	Journal Article
Language:	English
Published:	United States 15.12.2022
Subjects:	Animals Basic Helix-Loop-Helix Transcription Factors - metabolism Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - pathology Cell Line, Tumor Clinical Trials, Phase I as Topic Humans Kidney Neoplasms - drug therapy Kidney Neoplasms - genetics Kidney Neoplasms - pathology Mice Polycythemia RNA, Small Interfering - genetics
ISSN:	1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!